Patients with acute coronary syndrome on maintenance dose prasugrel had a reduction in high on-treatment platelet reactivity rates after a prasugrel reload strategy, according to a post hoc analysis of a prospective, randomized, open-label pharmacodynamic study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.
Vorapaxar, a novel, oral PAR-1 agonist that inhibits thrombin-induced platelet activation, was found to prolong occlusion time and shorten lysis time, with a favorable effect on thrombotic and thrombolytic status, results of a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, has found.
A novel formulation of omega-3 free fatty acids (OM3-FFA) at a dosage as low as 2g/d was effective and well tolerated in lowering non-high density lipoprotein cholesterol (non-HDL-C), triglycerides (TG), and other markers of cardiovascular risk—including Apo CIII and Lp-PLA2—in patients with persistent hypertriglyceridemia on statin therapy, according to a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.
Reduction of furosemide dose in stable patients with chronic heart failure (HF) is feasible, with no deterioration in clinical status, a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, has found.
Prasugrel, compared with high-dose clopidogrel, more effectively reduced the risk of vascular mortality or stent thrombosis following a percutaneous coronary intervention (PCI) in patients with high on-clopidogrel platelet reactivity (HPR), according to data presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.